EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Role Of Clinical Pharmacist In Identifying And Managing Drug-Drug Interactions In Critical Care Unit- An Interventional Study

Dr. Vanishree. P. Babladi, Dr. Pooja V salimath, Ambika Hirve, Bhavani Bhalki, Mohd Owais, Sushmitha Joy

Innovative Journal of Medical and Healthcare Research · 2025

DOI: 10.61808/ijmhr20 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Innovative Journal of Medical and Healthcare Research, 2025. Verfasst von Dr. Vanishree. P. Babladi und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The risk that one medication may change the effects of another when taken at the same time is known as a drug-drug interaction (DDI). Finding out how often and how serious pDDIs are among intensive care unit (ICU) patients is the primary goal of this research.Finding and controlling possible DDIs is the goal of the research. Additionally, assess how well the clinical pharmacist has handled any drug-drug interactions (DDIs) in the intensive care unit.Research Approach: The intensive care unit at Basaweshwar Teaching and General Hospital was the site of a prospective interventional trial that lasted for six months. Patients hospitalized to the intensive care unit were included in the study at random after the study requirements were considered. The results showed that out of 102 cases tested, 61 (or 59.80%) were male and 41 (or 40.29%) were female. Out of the total number of patients, 22 (or 21.57%) were between the ages of 61 and 70, and 21 (or 20.59%) were 75 and older. Of the 102 instances that were examined, 76 had DDIs. Of these, 124 (31.58%) had 1 DDI and 15 (19.74%) had 2 DDIs. Out of the 76 DDIs that were noticed, 143 (or 65.60%) were classified as major, 64 (or 29.36%) as moderate, and 5 (or 2.29%) as small. Out of the 52 DDIs that were accepted, 24 (or 31.58%) were not. For 52 of these DDIs, the advised actions were monitoring for 25 (or 48.08%) and changing the administration time for 17 (or 32.69%). The two most often interfering drugs are ondansetron and tramadol. Ondansetron and tramadol is the most frequent medicine combination, occurring 13 times, while atorvastatin and clopidogrel is the second most common, occurring 11 times. In addition, medication interactions were more common when the dosage of each medicine was raised.Our research leads us to believe that clinical pharmacists may help stop these DDIs in the ED. Adequate understanding of the most prevalent pDDIs to permit the health care.

Zitieren

APA

Babladi, D. V. P., salimath, D. P. V., Hirve, A., Bhalki, B., Owais, M., & Joy, S. (2025). Role Of Clinical Pharmacist In Identifying And Managing Drug-Drug Interactions In Critical Care Unit- An Interventional Study. Innovative Journal of Medical and Healthcare Research. https://doi.org/10.61808/ijmhr20

Vancouver

Babladi DVP, salimath DPV, Hirve A, Bhalki B, Owais M, Joy S. Role Of Clinical Pharmacist In Identifying And Managing Drug-Drug Interactions In Critical Care Unit- An Interventional Study. Innovative Journal of Medical and Healthcare Research. 2025. doi:10.61808/ijmhr20

BibTeX
@article{Babladi2025,
  author = {Babladi, Dr. Vanishree. P. and salimath, Dr. Pooja V and Hirve, Ambika and Bhalki, Bhavani and Owais, Mohd and Joy, Sushmitha},
  title = {Role Of Clinical Pharmacist In Identifying And Managing Drug-Drug Interactions In Critical Care Unit- An Interventional Study},
  journal = {Innovative Journal of Medical and Healthcare Research},
  year = {2025},
  doi = {10.61808/ijmhr20}
}
Kostenlos starten →